NCT05144698View on ClinicalTrials.gov

RAPA-201 Therapy of Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

August 1, 2021

Primary Completion Date

January 1, 2026

Study Completion Date

December 31, 2026

Conditions
Solid TumorSmall Cell and Non-small Cell Lung CancerHead and Neck CancerSquamous Cell Carcinoma of Oral CavitySquamous Cell Carcinoma of LarynxSquamous Cell Carcinoma of NasopharynxSquamous Cell Carcinoma of Other Specified Sites of SkinMalignant MelanomaEsophageal Squamous Cell Carcinoma
Interventions
BIOLOGICAL

RAPA-201 Rapamycin Resistant T Cells

Autologous Rapamycin-Resistant Th1/Tc1 Cells

DRUG

Chemotherapy Prior to RAPA-201 Therapy

Outpatient Carboplatin + Paclitaxel Regimen (CP Regimen)

DRUG

Pembrolizumab (PD-1 Blocking Antibody)

Drug Therapy After RAPA-201 Therapy

Trial Locations (1)

07601

RECRUITING

Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

Rapa Therapeutics LLC

INDUSTRY